Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014001 · ClinicalTrials.gov registry record · Phase 4
CATIE- Schizophrenia Trial
A Phase 4 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 1,600
- Enrollment target
NCT00014001 is a Phase 4 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 1,600 participants.
The verdict
NCT00014001, a Phase 4 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,600 participants
- Enrollment target
Study Summary
The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG quetiapine
- DRUG ziprasidone
- DRUG perphenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2000-12 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014001
The ClinicalTrials.gov registry entry for NCT00014001 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which risperidone is the first listed.
NCT00014001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014001 about?
NCT00014001 is a clinical study titled "CATIE- Schizophrenia Trial". The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people...
What is the current status of trial NCT00014001?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,600 participants. The study started on 2000-12. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00014001?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), quetiapine (DRUG), ziprasidone (DRUG), perphenazine (DRUG).
Who is sponsoring clinical trial NCT00014001?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.